Bristol-Myers Squibb Company
BMYBarron's: Bristol Myers in merger talks with AstraZeneca on potential $400 billion combination
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B |
| Cost of Revenue | $20.87B | $19.65B | $19.67B | $19.62B | $20.82B | $8.89B | $6.49B | $5.82B |
| Gross Profit | $27.43B | $25.36B | $26.49B | $26.76B | $21.70B | $17.25B | $16.07B | $14.96B |
| Gross Margin | 56.80% | 56.34% | 57.39% | 57.69% | 51.04% | 65.98% | 71.25% | 72.00% |
| Operating Expenses | $17.77B | $16.89B | $17.22B | $17.22B | $17.21B | $10.81B | $9.68B | $9.72B |
| Operating Income | $9.66B | $8.47B | $9.27B | $9.54B | $4.49B | $6.44B | $6.39B | $5.24B |
| Operating Margin | 20.00% | 18.82% | 20.08% | 20.57% | 10.56% | 24.63% | 28.34% | 25.22% |
| Net Income | $-8.95B | $8.03B | $6.33B | $6.99B | $-8.99B | $3.44B | $4.92B | $1.01B |
| Net Margin | -18.53% | 17.83% | 13.71% | 15.08% | -21.16% | 13.15% | 21.81% | 4.85% |
| EPS (Basic) | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.98 | $2.02 | $3.03 | $0.61 |
| EBITDA | $3.17B | $19.37B | $19.22B | $20.12B | $4.93B | $7.38B | $6.79B | $6.12B |
| Stock Option Compensation Expense | $507.00M | $518.00M | $457.00M | $583.00M | $779.00M | $441.00M | $221.00M | $199.00M |
| Price To Earnings Ratio | -12.81 | 13.23 | 24.22 | 19.80 | -15.57 | 31.82 | 17.25 | 100.10 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $114.65B | $106.16B | $153.25B | $138.48B | $140.06B | $109.44B | $84.88B | $100.81B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B |
| Total Liabilities & Stockholders Equity | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B |
| Book Value Per Share | $8.08 | $14.25 | $14.61 | $16.21 | $16.78 | $30.32 | $8.65 | $7.20 |
| Tangible Book Value Per Share | $-14.29 | $-9.26 | $-12.39 | $-12.28 | $-15.99 | $-20.39 | $3.98 | $2.29 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.66% | 8.43% | 6.53% | 6.40% | -7.59% | 2.65% | 14.06% | 3.00% |
| Return on Equity | -54.78% | 27.27% | 20.37% | 19.46% | -23.78% | 6.66% | 35.07% | 8.58% |
| Return on Invested Capital | 13.59% | 10.59% | 9.61% | 8.93% | 4.41% | 3.89% | 20.36% | 3.99% |
| Quick Ratio | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 1.55 | 1.43 |
| Current Ratio | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 1.66 | 1.55 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-8.95B | $8.03B | $6.33B | $6.99B | $-8.99B | $3.44B | $4.92B | $1.01B |
| Depreciation | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637.00M | $789.00M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B |
| Capital Expenditures | $1.25B | $1.21B | $1.12B | $973.00M | $753.00M | $836.00M | $951.00M | $1.05B |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $0.00 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320.00M | $2.47B |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.37B | $6.12B | $4.22B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.